

09/907,263

protein, celecoxib as the anti-inflammatory drug, and rheumatoid arthritis as the inflammatory disease. The claims readable on each election of species are as follows:


sTNF-RII as TNF binding protein--Claims 1, 27-33, 36, 37, 39-41;

celecoxib as anti-inflammatory drug--Claims 1 and 27-41;

rheumatoid arthritis as inflammatory disease--Claims 1 and 27-41.

Conclusion. The Applicants respectfully request entry of all amendments and allowance of all claims.

Respectfully submitted,



Timothy J. Saul
Attorney for Applicants
Registration No.: 33,111
Phone: (805) 447-2688
Date: September 10, 2002

Please send all future correspondence to:

US Patent Operations/ [TJG]
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799